EU adopts regulation to allow quick development of COVID-19 vaccine

The regulation that allows temporary derogation from certain rules for clinical trials was approved on Friday by 505 votes in favour, 67 against and 109 abstentions, following an urgent debate last week, Xinhua news agency reported.

Last month, the European Commission proposed a vaccine strategy that requests a temporary and strictly COVID-19-related derogation from certain rules for clinical trials of vaccines or treatments that contain or consist of genetically modified organisms (GMOs).

As national requirements to assess the environmental risks of clinical trials on medicinal products that contain or consist of GMOs vary considerably across member states, a derogation from these rules is needed to avoid significant delay in developing life-saving vaccines and treatments.

As of Friday, there have been 2,737,749 confirmed COVID-19 cases across the whole of Europe, according to the Statista online data collection portal.